Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease.
about
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.Nonmedical Switching of Biosimilars in Patients With Inflammatory Bowel Disease.The nocebo effect challenges the non-medical infliximab switch in practice.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.Biosimilars in paediatric inflammatory bowel diseaseNon-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies
P2860
Long-Term Clinical Outcomes After Switching from Remicade(®) to Biosimilar CT-P13 in Inflammatory Bowel Disease.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Long-Term Clinical Outcomes Af ...... in Inflammatory Bowel Disease.
@en
type
label
Long-Term Clinical Outcomes Af ...... in Inflammatory Bowel Disease.
@en
prefLabel
Long-Term Clinical Outcomes Af ...... in Inflammatory Bowel Disease.
@en
P2093
P2860
P1476
Long-Term Clinical Outcomes Af ...... in Inflammatory Bowel Disease.
@en
P2093
Anna Grelack
Aura A J van Esch
Dirk J de Jong
Frank Hoentjen
Joost P H Drenth
Lauranne A A P Derikx
Lisa J T Smits
Ronald S Boshuizen
P2860
P2888
P304
P356
10.1007/S10620-017-4661-4
P577
2017-06-30T00:00:00Z
P6179
1090321441